Financial Performance - The Company reported no revenue for the year ended December 31, 2025, a decrease of 100% compared to $500,000 in 2024[150]. - Exicure, Inc. reported total revenue of $0 for the year ended December 31, 2025, compared to $500,000 in 2024, indicating a 100% decrease in revenue[221]. - The net loss for 2025 was $4.946 million, a 49% improvement from a net loss of $9.701 million in 2024[163]. - Exicure, Inc. incurred a net loss of $4,946,000 in 2025, compared to a net loss of $9,701,000 in 2024, reflecting a 48.9% improvement in net loss[221]. - The accumulated deficit increased to $(204,210,000) in 2025 from $(199,264,000) in 2024, indicating a growing financial challenge[219]. - The company has an accumulated deficit of $223.0 million, with net losses of $4.9 million and $9.7 million for the years ended December 31, 2025 and 2024, respectively[65]. - The company's total operating expenses for 2025 were $4,233,000, a significant reduction from $12,732,000 in 2024, representing a 66.7% decrease[221]. - Total operating expenses decreased by 67% to $4.233 million in 2025, down from $12.732 million in 2024[163]. - General and administrative expenses increased by 25% to $6.831 million in 2025, up from $5.449 million in 2024[163]. - Research and development expenses for 2025 amounted to $3.286 million, a 100% increase from zero in 2024[163]. Cash and Financing - As of December 31, 2025, the company's cash and cash equivalents were approximately $3.7 million[53]. - The Company had approximately $3.7 million in cash and cash equivalents as of December 31, 2025, raising concerns about its ability to fund operations for the next 12 months[132]. - The company's cash, cash equivalents, and restricted cash decreased to $3,746,000 in 2025 from $12,508,000 in 2024, a decline of 70%[219]. - The Company expects to seek financing through equity offerings, but faces challenges due to its current condition and uncertainty over future direction[133]. - The company is exploring strategic alternatives, including private company acquisitions and raising additional capital[29]. - The company is exploring strategic alternatives and may need to seek bankruptcy protection if additional financing is not secured[180]. - The company has no current source of revenue and is dependent on obtaining substantial additional financing to support operations[53]. - The company may face challenges in raising additional capital through equity offerings or debt financings, which could lead to dilution for existing stockholders[86]. Operational Challenges - The company faces substantial doubt about its ability to continue as a going concern, requiring additional funding in the near term to support operations[60]. - The company has experienced significant turnover in its board and senior management, which may create uncertainty regarding its strategic direction and business priorities[58]. - The company has a significant working capital deficiency and has incurred substantial losses, raising doubts about its ability to continue as a going concern[213]. - The company received a payment demand letter for approximately $0.7 million in unpaid rent, which could impact its operational capabilities[73]. - The company has identified material weaknesses in its internal controls over financial reporting, which could lead to inaccuracies in financial statements[75]. - The company identified material weaknesses in its internal control over financial reporting, leading to the restatement of its unaudited interim condensed consolidated financial statements for Q1 and Q2 2023[78]. - The company incurred unanticipated costs for accounting and legal fees related to the restatement, which may continue to affect its financial condition and reputation[78]. Stock and Ownership - HiTron beneficially owns approximately 25% of the outstanding shares of common stock, significantly influencing the company, while CBI USA and DGP collectively own about 10%[80]. - The company has experienced an "ownership change" as defined by Section 382(g) during Q4 2022, which restricts its ability to use net operating loss carryforwards to offset taxable income[91]. - As of December 31, 2023, the company ceased operations of its historical business enterprise, resulting in a zero limitation on the use of historical net operating losses prior to the ownership change[94]. - The market price of the company's common stock has been highly volatile, influenced by various factors including the influence of significant stockholders and general market conditions[84]. - The company's common stock was approved for listing on the Nasdaq Capital Market under the symbol "XCUR" and began trading on July 31, 2019, with a last reported sale price of $4.54 per share on March 17, 2026[115]. - As of March 17, 2026, the company had 6,373,915 shares of common stock outstanding held by 88 stockholders of record[116]. - The company has never declared or paid cash dividends on its common stock and does not intend to do so for the foreseeable future[117]. Regulatory and Compliance Issues - The company has received multiple deficiency notices from Nasdaq regarding compliance with listing requirements, raising the risk of delisting[61]. - The Company has received deficiency notices from Nasdaq regarding compliance with listing requirements, but regained compliance by filing its Form 10-Q on June 27, 2025[137][138]. - Compliance with European data protection laws, including GDPR, is critical, as failure to comply may materially adversely affect the company's business and financial condition[79]. - The company is subject to risks related to government regulation, which could impact its operations and financial results[79]. - FINRA sales practice requirements may limit stockholders' ability to buy and sell the company's stock due to its low stock price, potentially affecting market activity[95].

Financial Performance - The company reported a net loss of $4.9 million for 2025, a reduction from a net loss of $9.7 million in 2024, largely due to a $6.0 million gain from lease liability reversal[8] - Total revenue for 2025 was $0, a decrease from $500,000 in 2024, reflecting a significant decline in operational performance[17] - Total operating expenses for 2025 were $4.2 million, down from $12.7 million in 2024, primarily due to reduced litigation and impairment losses[17] Cash and Liquidity - Cash and cash equivalents decreased to $3.7 million as of December 31, 2025, from $12.5 million as of December 31, 2024, indicating potential liquidity issues for the next 12 months[3] - The company has engaged in significant cost reductions and requires substantial additional financing in the short term to continue operations[9] Expenses - Research and development expenses for 2025 were $3.3 million, a significant increase from $0 in 2024, due to activities following the acquisition of GPCR Therapeutics USA Inc.[4] - General and administrative expenses rose to $6.8 million in 2025, up from $5.4 million in 2024, primarily due to costs associated with the acquisition and integration of GPCR USA[5] Shareholder Considerations - The weighted-average basic and diluted common shares outstanding increased to 6,297,094 in 2025 from 2,043,278 in 2024, indicating a potential dilution of shares[17] - The company is exploring strategic alternatives to maximize stockholder value following its restructuring and acquisition activities[10] Lease and Gains - The company recognized a $6.0 million gain from the early termination of its Chicago office lease, effective January 31, 2025[6]

Financial Overview - The company reported a cash position of $3.7 million as of December 31, 2025, down from $12.5 million as of December 31, 2024, indicating potential liquidity issues for the next 12 months [2] - The net loss for the year ended December 31, 2025, was $4.9 million, a decrease from a net loss of $9.7 million in 2024, primarily due to a $6.0 million gain from lease liability reversal [7] Research and Development - Research and development expenses increased to $3.3 million for the year ended December 31, 2025, compared to $0 in 2024, reflecting activities following the acquisition of GPCR Therapeutics USA Inc. [3] General and Administrative Expenses - General and administrative expenses rose to $6.8 million in 2025 from $5.4 million in 2024, driven by costs associated with the acquisition and integration of GPCR USA [4] Other Income and Expenses - The company recognized a $6.0 million gain from the early termination of its lease in Chicago, effective January 31, 2025 [5] - Other income included a $346,000 gain in Q3 2025 from satisfying self-insured retention, but there were losses totaling $1,553,000 related to changes in fair value of contingent liabilities and $275,000 from the sale of its subsidiary, KC Creation [6] Balance Sheet Highlights - Total assets decreased to $14.0 million as of December 31, 2025, from $15.1 million in 2024, with current assets also declining significantly [13][14] - Total liabilities increased to $10.1 million in 2025 from $8.3 million in 2024, with a notable rise in accounts payable and contingent consideration [13][14] Company Background - Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies. Following a restructuring, the company is exploring strategic alternatives to maximize stockholder value and has acquired a clinical-stage biotechnology company [9]

Core Insights - Exicure, Inc. announced positive results from a Phase 2 clinical study of burixafor, a selective CXCR4 inhibitor, demonstrating rapid lymphocyte mobilization and potential therapeutic applications beyond transplantation [1][2] Study Results - The Phase 2 study involved 12 participants with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin disease undergoing autologous stem cell transplantation, with 92% achieving the primary endpoint of collecting ≥5.0 × 10⁶ CD34+ cells/kg within two leukapheresis sessions [2][3] - Notably, 6 participants achieved the target in a single session, with median times to neutrophil and platelet engraftment recorded at 12 and 22 days, respectively [3] Mobilization Profile - Burixafor demonstrated peak mobilization of CD34+ cells within one hour of administration, significantly faster than existing CXCR4 inhibitors, which peak at 10-14 hours [4] - This rapid mobilization allows for same-day leukapheresis, potentially simplifying treatment logistics and reducing hospital resource utilization [4] Clinical Implications - The combination of burixafor and G-CSF resulted in substantial increases in circulating lymphocyte counts, with increases of up to 11-fold observed in multiple myeloma patients [5] - The study highlights burixafor's potential applicability in gene therapy and CAR-T cell therapies, which require efficient peripheral blood cell collection [5] Future Development - Exicure is advancing burixafor's clinical development, having completed an additional Phase 2 study combining burixafor with G-CSF and propranolol, with positive topline data presented at recent hematology meetings [6] - The company aims to leverage burixafor's capabilities in various hematologic diseases, including plans for a chemosensitization trial in acute myeloid leukemia [8]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Premarket Gainers - Silicon Laboratories Inc. (SLAB) is up 49% at $204.51 [3] - Concorde International Group Ltd. (CIGL) is up 44% at $3.90 [3] - ENvue Medical, Inc. (FEED) is up 25% at $3.08 [3] - Enphase Energy, Inc. (ENPH) is up 23% at $46.06 [3] - Digital Turbine, Inc. (APPS) is up 18% at $5.85 [3] - Tandy Leather Factory, Inc. (TLF) is up 16% at $3.35 [3] - Lumentum Holdings Inc. (LITE) is up 12% at $487.60 [3] - Super Micro Computer, Inc. (SMCI) is up 10% at $32.66 [3] - Sonos, Inc. (SONO) is up 10% at $16.17 [3] - Exicure, Inc. (XCUR) is up 9% at $4.52 [3] Premarket Losers - Intapp, Inc. (INTA) is down 16% at $24.50 [4] - Texxon Holding Limited (NPT) is down 15% at $6.08 [4] - Varonis Systems, Inc. (VRNS) is down 14% at $22.59 [4] - Mercury Systems, Inc. (MRCY) is down 11% at $88.00 [4] - Boston Scientific Corporation (BSX) is down 9% at $82.80 [4] - nLIGHT, Inc. (LASR) is down 9% at $45.10 [4] - Advanced Micro Devices, Inc. (AMD) is down 8% at $220.84 [4] - NGL Energy Partners LP (NGL) is down 7% at $10.98 [4] - MKDWELL Tech Inc. (MKDW) is down 7% at $2.67 [4] - Wabash National Corporation (WNC) is down 6% at $10.54 [4]

Core Insights - Exicure, Inc. is set to present at the 2026 Tandem Meetings, showcasing data from its Phase 2 trial of burixafor for multiple myeloma patients undergoing autologous hematopoietic cell transplantation [1][2] Group 1: Company Overview - Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematologic diseases, with its lead program being burixafor, a selective antagonist of the CXCR4 receptor [5] - Burixafor aims to enhance stem cell mobilization into peripheral blood, facilitating collection for autologous hematopoietic cell transplantation [5][6] Group 2: Clinical Trial Insights - The Phase 2 trial (NCT05561751) evaluated burixafor's effectiveness in mobilizing hematopoietic progenitor cells by blocking CXCR4, which retains stem cells in the bone marrow [2][3] - The trial reported that 89.7% of patients met the primary endpoint, demonstrating reliable mobilization and a favorable safety profile when burixafor was used in combination with propranolol and G-CSF [3][4] Group 3: Future Directions - Exicure is exploring burixafor's potential in other conditions, including sickle cell disease and acute myeloid leukemia, where it may help mobilize malignant cells for more effective chemotherapy [6]

Company Performance - AutoZone, Inc. (NYSE:AZO) stock fell approximately 7% after reporting first-quarter earnings and sales that did not meet Wall Street expectations, with earnings per share at $31.04, below the consensus estimate of $32.37, and quarterly sales of $4.629 billion, which was an 8.2% year-over-year increase but missed the expected $4.637 billion [2] Market Movements - Alexander & Baldwin, Inc. (NYSE:ALEX) shares surged 38% to $20.89 following the announcement of a $2.3 billion all-cash deal to go private [8] - Exicure Inc (NASDAQ:XCUR) shares increased by 35% to $7.10 after positive results from a Phase 2 trial related to multiple myeloma treatment [8] - Tronox Holdings plc (NYSE:TROX) shares rose 30% to $4.86 after receiving non-binding letters of support for up to $600 million in financing for its rare earth supply chain development [8] - Top Wealth Group Holding Ltd (NASDAQ:TWG) shares plummeted 71% to $6.31 after announcing a public offering priced at $7.00 per unit [8] - Phreesia, Inc. (NYSE:PHR) shares fell 21% to $15.80 following third-quarter results [8] - SLM Corporation (NASDAQ:SLM) shares decreased by 16% to $25.86 after a downgrade from Buy to Sell and a reduction in price target from $35 to $23 [8] Economic Indicators - U.S. private employers added an average of 4,750 jobs per week during the four weeks ending November 22 [10] - U.S. job openings increased by 12,000 to 7.670 million in October, compared to 7.658 million in September [10]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite gaining approximately 50 points on Tuesday. The Dow rose by 0.22% to 47,845.80, the NASDAQ increased by 0.22% to 23,597.71, and the S&P 500 climbed 0.23% to 6,862.11 [1] - Energy shares saw a notable increase of 1.5%, while health care stocks declined by 0.4% on the same day [1] Company Earnings - AutoZone, Inc. (NYSE:AZO) reported a decline in stock value by around 7% after its first-quarter earnings and sales fell short of Wall Street expectations. The company reported earnings per share of $31.04, missing the consensus estimate of $32.37. Quarterly sales reached $4.629 billion, reflecting an 8.2% year-over-year increase, but still fell short of the expected $4.637 billion [2] Notable Stock Movements - Alexander & Baldwin, Inc. (NYSE:ALEX) shares surged by 38% to $20.89 following the announcement of a $2.3 billion all-cash deal to go private [8] - Exicure Inc (NASDAQ:XCUR) shares increased by 35% to $7.10 after positive results from a Phase 2 trial related to multiple myeloma treatment [8] - Tronox Holdings plc (NYSE:TROX) shares rose by 30% to $4.86 after receiving non-binding letters of support for financing up to $600 million for its rare earth supply chain development [8] - Top Wealth Group Holding Ltd (NASDAQ:TWG) shares plummeted by 71% to $6.31 after announcing a public offering priced at $7.00 per unit [8] - Phreesia, Inc. (NYSE:PHR) shares fell by 21% to $15.80 following third-quarter results [8] - SLM Corporation (NASDAQ:SLM) experienced a decline of 16% to $25.86 after a downgrade from Compass Point and Morgan Stanley, with price targets reduced significantly [8] Commodity Market - In commodity trading, oil prices decreased by 1.1% to $58.23, while gold prices increased by 0.7% to $4,248.20. Silver saw a rise of 4.5% to $61.005, whereas copper prices fell by 2.2% to $5.3275 [5] European Market Performance - European shares showed mixed results, with the eurozone's STOXX 600 declining by 0.10%. Spain's IBEX 35 Index rose by 0.13%, while London's FTSE 100 fell by 0.03%, Germany's DAX 40 gained 0.49%, and France's CAC 40 decreased by 0.69% [6] Asian Market Performance - Asian markets closed mostly lower, with Japan's Nikkei rising by 0.14%, while Hong Kong's Hang Seng fell by 1.29%, China's Shanghai Composite declined by 0.37%, and India's BSE Sensex decreased by 0.51% [9] Employment Data - U.S. private employers added an average of 4,750 jobs per week during the four weeks ending November 22. Job openings rose by 12,000 to 7.670 million in October, compared to 7.658 million in September [10]

Core Insights - Exicure, Inc. (NASDAQ:XCUR) stock experienced a significant increase of 63.23%, reaching $8.70, following the announcement of positive results from its Phase 2 trial of burixafor in multiple myeloma patients [6] Group 1: Trial Results - Approximately 90% of study participants achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions [2][3] - Among the 19 participants, 17 (89.5%) met the primary endpoint, with two requiring an additional session to achieve the target [3] - The median time to neutrophil engraftment was 13 days, and the median time to platelet engraftment was 17.5 days for those who proceeded to transplant [4] Group 2: Mechanism and Efficacy - Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors, facilitating rapid mobilization of hematopoietic progenitor cells from the bone marrow [2] - The combination of burixafor with propranolol enhanced mobilization by inhibiting the β2-adrenergic receptor [3] - Peak peripheral levels of CD34+ cells were observed within one hour of burixafor administration, allowing for same-day administration and apheresis [4] Group 3: Safety Profile - The burixafor combination was well tolerated, with no related adverse events exceeding Grade 2 [6] - Among participants with prior exposure to daratumumab, 87.5% achieved the primary endpoint, indicating the treatment's effectiveness even in previously treated patients [5]

Core Viewpoint - Exicure has experienced a significant stock price rally due to promising Phase 2 trial results for its investigational drug burixafor, which is designed for hematopoietic progenitor cell mobilization in multiple myeloma patients [1][3]. Group 1: Stock Performance - Exicure shares surged 70% in pre-market trading to approximately $9, following a previous close of $5.33, marking a year-to-date decline of 64.89% [1]. - The early-morning rally was a response to the positive trial results, indicating a strong market reaction to the new data [3]. Group 2: Clinical Trial Results - Nearly 90% of trial participants achieved the required CD34+ cell thresholds within two leukapheresis sessions when treated with burixafor in combination with propranolol and G-CSF [4]. - The therapy demonstrated effectiveness in patients previously treated with daratumumab, a group that typically has lower mobilization success [5]. - Burixafor's rapid activity was highlighted, with peak CD34+ cell levels appearing within an hour, distinguishing it from other drugs in the same class [5]. Group 3: Institutional Ownership - Despite its small size and previous decline, Exicure has maintained a presence in the portfolios of major institutional investors, including BlackRock, Carlyle Group, Vanguard, Geode Capital Management, and UBS Group [6][7]. - As of September 30, 2025, BlackRock held 5,730 shares of Exicure, indicating continued interest from professional investors [6].